Healthcare - Biotechnology - NASDAQ - US
$ 3.1
-15.5 %
$ 28.6 M
Market Cap
-0.49
P/E
CASH FLOW STATEMENT
-25.1 M
OPERATING CASH FLOW
-153 K
INVESTING CASH FLOW
66.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
SAB Biotherapeutics, Inc.
| Net Income | -42.2 M |
| Depreciation & Amortization | 3.75 M |
| Capital Expenditures | -197 K |
| Stock-Based Compensation | 2.42 M |
| Change in Working Capital | 2.33 M |
| Others | 8.05 M |
| Free Cash Flow | -25.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (42.2) | (17.1) | (17.1) | 20.1 | (9.0) |
| Depreciation & Amortization | 3.7 | 1.7 | 1.7 | 0.5 | 0.3 |
| Deferred Income Tax | 0 | 0 | 0 | 2.25 K | 421 |
| Stock Based Compensation | 2.4 | 2.7 | 2.3 | 1.3 | 0.4 |
| Other Operating Activities | 8.6 | 3.5 | 3.5 | 2 | 1 |
| Change in Working Capital | 2.3 | 13.5 | 13.5 | (12.0) | (0.9) |
| Cash From Operations | (25.1) | 3.8 | 3.8 | 10.0 | (9.2) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.2) | (10.9) | (10.9) | (12.7) | (0.6) |
| Other Items | 44.4 K | 0 | 0 | 9 K | 0 |
| Cash From Investing Activities | (0.2) | (10.9) | (10.9) | (12.7) | (0.6) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | (5.5) | 0 | 0 | 0 |
| Total Debt Repaid | (0.4) | (1.2) | 1.5 | (0.9) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 67.2 | 77 K | 32.6 | 9.9 | 0 |
| Cash From Financing Activities | 66.8 | 34.1 | 34.1 | 9.0 | 3.7 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 41.5 | 26.9 | 26.9 | 6.3 | (6.1) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (25.3) | (7.2) | (7.2) | (2.7) | (9.8) |